Evidence map›Paper›PMID 26587375›Full record

ArticleJournal of bone oncology2015

The role of 18F-NaF PET/CT in metastatic bone disease.

Mine Araz, Gülseren Aras, Özlem N Küçük

Open access · goldAbstract read
In one paragraph

Article in Journal of bone oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Advances in GPCR-Targeted PET Radiotracer Patents (2020-2025).Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Quantitative aortic Na[European journal of nuclear medicine and molecular imaging · 2025
    Article
  11. Structural and molecular imaging-based characterization of soft tissue and vascular calcification in hyperphosphatemic familial tumoral calcinosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Article
  12. Article
  13. Breast PET/MRI Hybrid Imaging and Targeted Tracers.Journal of magnetic resonance imaging : JMRI · 2023
    Review
  14. Quantitative [EJNMMI physics · 2022
    Article
  15. Preparation, Optimisation, and In Vitro Evaluation of [Molecules (Basel, Switzerland) · 2022
    Article
  16. Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  17. Application ofQuantitative imaging in medicine and surgery · 2022
    Article
  18. Article
  19. Comparison of Bone Metastases betweenContrast media & molecular imaging · 2022
    Article
  20. Novel Application ofFrontiers in medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mine ArazAnkara University Medical Faculty Nuclear Medicine Department, Cebeci Hospital, Cebeci, 06590, Ankara, Turkey.
Gülseren ArasAnkara University Medical Faculty Nuclear Medicine Department, Cebeci Hospital, Cebeci, 06590, Ankara, Turkey.
Özlem N KüçükAnkara University Medical Faculty Nuclear Medicine Department, Cebeci Hospital, Cebeci, 06590, Ankara, Turkey.
Ankara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the role of 18F-NaF PET/CT and compare it with 99m Tc-MDP whole body bone scintigraphy and 18F-FDG PET/CT in detecting the extent of metastatic bone disease and to present our first experience with 18F-NaF PET/CT in our country. MATERIALS AND

methodsA total of 37 histopathologically proven cancer patients (22 male, 15 female) with bone metastasis detected on Tc-99m MDP whole body bone scan were prospectively enrolled Cebeci, following ethics committee approval. 18F-NaF PET/CT was performed to the participants in Ankara University Medical Faculty Nuclear Medicine Department for evaluation of symptomatic skeletal sites which were negative on Tc-99m MDP whole body bone scan. A lesion based comparison was made between 18F-NaF PET/CT and Tc-99m MDP whole body bone scan for each patient and between 18F-NaF PET/CT and 18F-FDG PET/CT in 12/37 patients.

resultsThe number of lesions demonstrated by 99m Tc-MDP bone scan and 18F-NaF PET/CT was equal in 4/37 (%11) of the cases. 18F-NaF PET/CT showed a greater number of pathological foci in 89% of participants. 18F-NaF PET/CT was able to show both lytic and blastic lesions and small lesions were better visualized due to the advantage of sectional imaging with much better resolution and higher target/background ratio. 18F-NaF PET/CT demonstrated a greater number of metastases in 10/12 (83%) of the patients when compared to 18F-FDG PET/CT. In the other two patients, bone metastasis could be demonstrated only by 18F-NaF PET/CT. The uptake of 18F-FDG was variable in blastic lesions and cranial bone involvement was missed by 18F-FDG PET/CT in some cases due to physiological brain metabolism.

conclusionAlthough further prospective clinical studies in specific cancer populations are indicated to set the place of 18F-NaF PET/CT in diagnostic scheme, the results of this pilot study from our country support the superiority of 18F-NaF PET/CT in investigation of bone metastasis over 99mTc-MDP bone scan and 18F-FDG PET/CT in various malignancies. 18F-NaF PET/CT is coming forward as a single step bone seeking study, considering all the advantages, but especially potential of detecting occult metastases and reliably directing patient management.

Indexed as

18F-FDG PET/CT18–NaF PET/CT99mTc- MDP whole body bone scintigraphyBone metastasesBone oncologyDiagnosis

Identifiers

PMID26587375
PMCPMC4648995
OpenAlexW1673528503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.